An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects

AIMS: XEN-D0501, a novel TRPV1 antagonist, is being developed to treat overactive bladder. This study investigated the safety and pharmacokinetics of repeat-dose XEN-D0501 in healthy subjects. METHODS: The study was conducted in two parts. Part 1 was a double-blind, randomized, placebo-controlled, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Round, Patrick, Priestley, Anthony, Robinson, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2011
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244639/
https://www.ncbi.nlm.nih.gov/pubmed/21676011
http://dx.doi.org/10.1111/j.1365-2125.2011.04040.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244639/
https://www.ncbi.nlm.nih.gov/pubmed/21676011
http://dx.doi.org/10.1111/j.1365-2125.2011.04040.x

Ejemplares similares